

论文

吩噻嗪类化合物抑制肿瘤细胞多药耐药及蛋白激酶C活性的三维构效关系研究

彭晖;杨纯正;梁巍;齐静;黄牛;郭宗儒

中国医学科学院、中国协和医科大学血液学研究所, 天津 300020; 1.中国医学科学院、中国协和医科大学药物研究所, 北京 100050

摘要:

目的: 利用本室诱导建立的耐药细胞株K562/A02,研究在体外条件下吩噻嗪类衍生物(PTZs)逆转多药耐药(MDR)活性的构效关系。方法与结果: 利用已知PKC Cys 2功能区晶体结构, 结合计算化学和分子图形学手段对PKC抑制剂与PKC蛋白分子间可能的相互作用模式进行探讨。结果表明, 2位取代各种基团逆转MDR作用强度依次为: COC₃H₇>CF₃>COCH₃>H。边链哌嗪环4'-位取代基作用强度为:CH₃>COOC₂H₅>C₂H₄OH。结论: 选出代表性化合物测定对鼠脑的抑制活性, 初步三维构效关系研究表明, PTZs抑制PKC活性确实与特定的立体结构特征有关。本研究为进一步探索PTZs, PKC和MDR三者间的内在机制和设计有效PKC抑制剂或多药耐药逆转剂提供了新的途径。

关键词: 吩噻嗪类衍生物 多药耐药 逆转剂 蛋白激酶C

STRUCTURE-ACTIVITY RELATIONSHIP OF PHENOTHIAZINES FOR INHIBITION OF PROTEIN KINASE C AND REVERSAL OF MULTIDRUG RESISTANCE

Peng Hui; Yang Chunzheng; Liang Wei Qi Jing;Huang Niu and Guo Zongru

Abstract:

AIM: To study the structure-activity relationship of phenothiazines(PTZs) for inhibition of protein kinase C (PKC) and reversal of multidrug resistance (MDR) *in vitro*. METHODS and RESULTS: The possible binding model of PTZs to PKC based upon the X-ray structure of PMA(phorbol myristic acetate) in complex with PKC Cys 2 with DOCK program was explored. The results showed that the order of potency of reversal effect of PTZs on MDR is as follows: 2-COC₃H₇>2-CF₃>2-COCH₃>H. The type of piperazinyI substitution also significantly affected potency against MDR. The result showed the order: CH₃>COOC₂H₅>C₂H₄OH. CONCLUSION: Some derivatives of PTZ was tested for inhibition of PKC. The observation indicates that PTZs inhibit PKC in a manner related to specific structural feature. Our molecular-modeling study suggests preliminarily how these PTZs bind to PKC and provide a structural basis for the design of high affinity PKC-modulator. Our structure-activity studies offer a way to understand which molecular structure affects activity, and this information may be used in the rational design of more effective drugs.

Keywords: multidrug resistance reversal agent protein kinase C phenothiazines

收稿日期 1998-01-23 修回日期 网络版发布日期

DOI:

基金项目:

通讯作者: 杨纯正

作者简介:

参考文献:

本刊中的类似文章

文章评论 (请注意:本站实行文责自负, 请不要发表与学术无关的内容!评论内容不代表本站观点.)

扩展功能

本文信息

- ▶ Supporting info
- ▶ PDF(226KB)
- ▶ [HTML全文]
- ▶ 参考文献

服务与反馈

- ▶ 把本文推荐给朋友
- ▶ 加入我的书架
- ▶ 加入引用管理器
- ▶ 引用本文
- ▶ Email Alert
- ▶ 文章反馈
- ▶ 浏览反馈信息

本文关键词相关文章

- ▶ 吩噻嗪类衍生物
- ▶ 多药耐药
- ▶ 逆转剂
- ▶ 蛋白激酶C

本文作者相关文章

- ▶ 彭晖
- ▶ 杨纯正
- ▶ 梁巍
- ▶ 齐静
- ▶ 黄牛
- ▶ 郭宗儒

PubMed

- ▶ Article by
- ▶ Article by
- ▶ Article by
- ▶ Article by
- ▶ Article by
- ▶ Article by

反馈人	<input type="text"/>	邮箱地址	<input type="text"/>
反馈标题	<input type="text"/>	验证码	<input type="text" value="3716"/>